NASDAQ NMS - GLOBAL MARKET · BTAI
-0.07% · -$0.0006 · Vol 319.0K
After hours · updated 16:29:01 ET
BioXcel Therapeutics Inc

BioXcel Therapeutics Inc

Biotechnology
$0.8600
Card
Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factorsMethodology
BTAI
BioXcel Therapeutics Inc
Stale score · Tue Aug 4 · completed session · 22h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
AVOID

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

25/ 100
Veridion Score
AVOID · HIGH confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Stale score · Tue Aug 4 · completed session · 22h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is BTAI moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading BTAI catalysts
About BioXcel Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2018
Employees
29
Country
US

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.8700
Day high
$0.8860
Day low
$0.8400
Previous close
$0.8606
52W high
$6.80
-87.35% from high
52W low
$0.7928
1% of range
Market cap
$26.6M
EPS
$-6.6700
Beta
1.89
Shares out
30.9M
Volume
319K
0.28× rel vol
Avg volume
1.1M
VWAP
$0.8646
Price history computed in-house
1W
+7.18%
1M
-21.82%
3M
-30.65%
1Y
-71.04%
YTD
-46.25%
SMA 50 $1.07 · below
SMA 200 $1.48 · below
52W position 1%

BTAI overview

Veridion Score
25
6 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around BTAI.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading BTAI Form 4 filings
Public disclosures

Congress activity in BTAI

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for BTAI in the cached public ledger.

Federal contracts

BTAI contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for BTAI in this window.
Lobbying spend

BTAI lobbying filings, year to date.

Registered lobbying filings matched to BioXcel Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for BTAI in this window.
Loading news for BTAI
Analyst ratings
Sovereign unlock shows live analyst consensus for BTAI.
Options
Sovereign unlock shows live options positioning for BTAI.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.